CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
- Autores: Alvarez C, Brassat D, Decanine D, Galvão-Castro B, Gotuzzo E, Khouri R, Kruschewsky R, Liblau R, López G, Menezes SM, Schnitman SV, Talledo M, Vandamme AM, Weyenbergh JV
- Ano de Publicação: 2014
- Journal: Journal of Neuroinflammation
- Link: http://www.jneuroinflammation.com/content/11/1/18
Human T-cell lymphotropic virus (HTLV-1) is the causative agent of the incapacitating, neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Currently, there are no disease-modifying therapies with long-term clinical benefits or validated biomarkers for clinical follow-up in HAM/TSP.